Bristol-Myers Squibb has become the latest drug maker to post lower revenue, announcing a fourth-quarter sales decline of nearly 3 percent, to $5.02 billion, as competition increased for the cholesterol-lowering drug Pravachol, its second-biggest seller. As uncertainties seemed to mount, Bristol-Myers on Wednesday also predicted lower sales and earnings for 2006, with generic competition and patent losses significantly weighing down sales.

International Herald Tribune (http://www.iht.com/articles/2006/01/26/business/bristol.php)